BIRMINGHAM, ENGLAND — February 26, 2002 — In the first clinical study of its kind examining the use of drug therapy to improve erectile function in men who had undergone nerve-sparing radical prostatectomy, patients taking vardenafil reported statistically significant improvement in erectile function.
Among men who had undergone bilateral nerve-sparing surgery, 71 percent of those taking vardenafil 20 mg experienced improved erections.
Vardenafil is an investigational treatment for erectile dysfunction (ED) discovered by Bayer AG and will be co-promoted and co-developed with GlaxoSmithKline plc (GSK). Vardenafil is being evaluated in a broad range of patient populations, including difficult-to-treat patients.
The new data, presented at the 17th Annual Congress of the European Association of Urology (EAU), are important because at least one third of men with prostate cancer who undergo nerve-sparing radical prostatectomy experience ED. Since 1991, radical prostatectomy has been the most common treatment for localized and regional cancers(1). According to the American Cancer Society, 189,000 new cases of prostate cancer will be diagnosed this year. ..
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!